HFpEF remains a challenging clinical syndrome to even define, let alone treat. This session will review how to define HFpEF for clinical practice and study design, how to integrate current diagnostic tools optimally, and how to apply existing and new technologies to advanced phenotyping of HFpEF.

Learning Objectives:

1. Review the clinical and physiologic information provided by currently available diagnostic techniques in the evaluation of HFpEF.
2. Assess the indications for techniques in the clinical evaluation of patients with HFPEF.
3. Recognize the potential of these techniques for the assessment of drug effects in clinical trials.

Thus, there is an unmet need for new inotropic strategies. This session will review the clinical need for new inotropic strategies, the basic science underpinning novel strategies for enhancing cardiac contractility, and emerging date from proof-of-concept pre-clinical clinical research. Target audience is primarily physician and non-physician practitioners who care for patients with severe or unstable heart failure syndromes. Additionally, this session will be of value for clinical trainees and scientists involved with early and late therapeutic drug development.